News and Updates

The Breakthrough T1D New England Center of Excellence will focus on protecting the stem cell-derived beta cells from rejection by the immune system after transplantation.

Type 1 diabetes is one of the only major autoimmune diseases that doesn't have a disease-modifying therapy. A Breakthrough T1D clinical trial is aiming to change that.

Vertex Pharmaceuticals will launch a clinical trial of VX-880, a stem cell-derived beta cell therapy in type 1 diabetes (T1D).

Douglas Melton, Ph.D., can now produce unlimited quantities of beta cells. He now wants to evade the immune attack. See our video to find out more.

The FDA regulatory review is now under way for teplizumab, to prevent or delay T1D in at-risk individuals. The target action date is July 2, 2021.

It’s been a tough year, to say the least. But there’s news that we can be proud of in type 1 diabetes research and advocacy. Really proud of.

Dr. Robert Langer co-founded Moderna, who gained emergency use approval for its COVID vaccine. Watch the video to find out how Breakthrough T1D is helping to advance his research.

A Breakthrough T1D-funded clinical trial will test if a JAK inhibitor will preserve beta cell function in children and young adults with recently diagnosed T1D.

“We’ve been too focused on [insulin],” Jeremy Pettus, M.D., an endocrinologist at UC San Diego, says. Watch the video to find out why.

JDRF-funded researchers have discovered a protein on immune cells that, when it is disabled, could halt immune cell memory.